8-K: Protagonist Therapeutics Reports Positive Phase 3 Rusfertide Data and First Quarter 2025 Financial Results

Protagonist Therapeutics announces positive top-line results from the rusfertide Phase 3 VERIFY trial and reports a strong cash position of $697.9 million as of March 31, 2025.

Summary

• Protagonist Therapeutics reported its first quarter 2025 financial results on May 6, 2025.
• The company announced positive top-line results from the Phase 3 VERIFY trial of rusfertide in polycythemia vera (PV).
• The company also announced positive top-line results from the Phase 2b ANTHEM trial of icotrokinra in ulcerative colitis (UC).
• As of March 31, 2025, Protagonist Therapeutics had $697.9 million in cash, cash equivalents, and marketable securities.
• The company anticipates this cash runway will last through at least the end of 2028.
• License and collaboration revenue for the first quarter of 2025 was $28.3 million, compared to $255.0 million for the same period in 2024.
• The net loss for the first quarter of 2025 was $11.7 million, or $0.19 per share, compared to net income of $207.3 million, or $3.41 per share, for the first quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a strong financial position, indicating a favorable outlook for the company. However, the net loss for the quarter tempers the overall sentiment slightly.

Positives

• Positive top-line results from the Phase 3 VERIFY trial of rusfertide in PV were announced.
• Positive top-line results from the Phase 2b ANTHEM trial of icotrokinra in ulcerative colitis were announced.
• The company has a strong cash position of $697.9 million as of March 31, 2025, providing a cash runway through at least the end of 2028.
• The company is progressing its pre-clinical candidates, including the oral IL-17 antagonist PN-881, and oral anti-obesity and oral hepcidin programs.
• Data from the Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) was presented at the 2025 AAD Meeting in March.

Negatives

• The company reported a net loss of $11.7 million for the first quarter of 2025, compared to net income of $207.3 million for the same period in 2024.
• License and collaboration revenue decreased to $28.3 million for the first quarter of 2025, compared to $255.0 million for the same period in 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated.
• These risks include the company's ability to develop and commercialize its product candidates, earn milestone payments, obtain regulatory approval, and compete successfully against competitors.

Future Outlook

The company anticipates its cash, cash equivalents, and marketable securities will provide a cash runway through at least the end of 2028. The company is also focused on advancing its pre-clinical candidates, including PN-881, and oral anti-obesity and oral hepcidin programs.

Management Comments

• Protagonist is off to a very strong 2025 with multiple transformational events in the first quarter for our two late-stage partnered assets, rusfertide and icotrokinra which are progressing to NDA filings by year end, said Dinesh V. Patel, Ph.D., the Company's President and CEO.
• We look forward to presenting data from rusfertides Phase 3 VERIFY study at a plenary session at ASCO on June 1st.
• Were very pleased with the highly positive results from the icotrokinra Phase 2b ANTHEM study in ulcerative colitis which lay the foundation for additional studies in both UC and Crohns.
• We are continuing to increasingly focus on advancement of our pre-clinical candidates including the oral IL-17 antagonist PN-881, as well as additional candidates emerging from our oral anti-obesity and oral hepcidin programs.
• We are fortunate to be in a very strong cash position, allowing us to independently and rapidly progress our early-stage pipeline into value-creating clinical safety and proof-of-concept studies starting with PN-881 in 2025.

Industry Context

Protagonist Therapeutics is focused on developing novel peptide therapeutics. The positive results from the rusfertide and icotrokinra trials position the company well in the competitive landscape of treatments for polycythemia vera and ulcerative colitis, respectively. The company's strong cash position allows it to advance its pipeline and potentially compete with larger pharmaceutical companies.

Comparison to Industry Standards

• Rusfertide's Phase 3 VERIFY trial results are promising compared to existing treatments for polycythemia vera, such as phlebotomy and cytoreductive agents like hydroxyurea.
• Icotrokinra, as an oral IL-23 receptor antagonist, could offer a more convenient and targeted approach compared to existing injectable biologics for ulcerative colitis, such as anti-TNF antibodies (e.g., Humira, Remicade) and anti-integrin antibodies (e.g., Entyvio).
• The company's cash runway through at least the end of 2028 provides a significant advantage compared to smaller biotech companies that often face near-term funding challenges.

Stakeholder Impact

• Shareholders: Positive clinical trial results and strong cash position are likely to be viewed favorably.
• Employees: Continued progress in clinical development and a secure financial position can boost morale and job security.
• Patients: Potential for new and improved treatments for polycythemia vera and ulcerative colitis.
• Partners: Continued collaboration with Takeda and J&J on rusfertide and icotrokinra, respectively.

Next Steps

• Presentation of rusfertide Phase 3 VERIFY study data at ASCO on June 1st.
• Investor conference call on June 2nd to discuss rusfertide data.
• Presentation of full data set from icotrokinra Phase 2b ANTHEM trial at a medical conference later in 2025.
• Advancement of pre-clinical candidates, including PN-881, into clinical safety and proof-of-concept studies.

Key Dates

Keywords

rusfertide, icotrokinra, polycythemia vera, ulcerative colitis, clinical trials, financial results, Protagonist Therapeutics, VERIFY, ANTHEM, cash runway